Alecensa Doubles Time to Disease Progression in Untreated ALK+ NSCLC Patients Compared to Xalkori
News
Genentech’s Alecensa (alectinib) reduced the risk of disease progression or death by 53 percent compared to Xalkori (crizotinib) — the standard of care treatment for advanced ALK-positive non-small cell lung cancer (NSCLC) — concludes the ... Read more